Last updated: February 19, 2026
Amikacin sulfate is an aminoglycoside antibiotic used primarily for severe bacterial infections, especially those caused by multidrug-resistant strains. Multiple manufacturers globally produce amikacin sulfate, often through licensing agreements with key patent holders or as generic equivalents.
Major Suppliers and Manufacturers
Global Market Leaders
| Company / Manufacturer |
Country |
Manufacturing Capacity |
Notes |
| Hikma Pharmaceuticals |
Jordan |
High |
Produces under multiple brand names, including Amikin |
| Mylan (now part of Viatris) |
USA |
High |
Manufactures generic amikacin sulfate |
| Teva Pharmaceutical Industries |
Israel |
High |
One of the leading global generic drug producers |
| Pfizer Inc. |
USA |
Moderate |
Supplies through licensing agreements |
| Chengdu Asymchem Science Co., Ltd |
China |
Increasing |
Expanding production capacity for injectable antibiotics |
| Zhejiang Huahai Pharmaceutical |
China |
Increasing |
Focuses on antibiotics including amikacin sulfate |
Regional / Local Suppliers
- Sun Pharmaceutical Industries: India
- Glenmark Pharmaceuticals: India
- Aurobindo Pharma: India
- Zhejiang Tianyang Pharmaceutical: China
Licensing and Patent Status
Amikacin sulfate, originally developed by pharmaceutical companies like Eli Lilly, is now produced as a generic drug. Patents expired in many jurisdictions, allowing multiple manufacturers to produce the drug without licensing restrictions.
Supply Chain Infrastructure
- Raw Material Suppliers: Chinese and Indian suppliers of kanamycin, the precursor for amikacin.
- Formulation Facilities: Located predominantly in India, China, Israel, and the US.
- Distribution Channels: Global wholesalers, hospital pharmacies, and OEMs.
Regulatory Approvals and Certifications
Manufacturers must meet regulatory standards such as:
- US FDA approvals or compliance with the FDA's current Good Manufacturing Practices (cGMP).
- EMA registration or adherence to European Union standards.
- WHO prequalification for procurement by UN agencies.
Market Dynamics
- The global amikacin sulfate market was valued at approximately USD 250 million in 2021.
- CAGR projected at 4.5% from 2022 to 2027.
- Increasing antibiotic resistance drives demand.
Quality and Price Variability
Price per vial (1g dose):
| Supplier |
Average Price (USD) |
Certification Status |
| Hikma Pharmaceuticals |
4.50–6.00 |
WHO-GMP, US FDA-approved |
| Teva |
4.80–6.20 |
US FDA, European GMP |
| Chinese generic manufacturers |
3.50–4.50 |
CE Mark, local approvals |
Quality standards influence procurement decisions, especially for public health agencies and hospitals.
Summary
Multiple global companies supply amikacin sulfate, with leading manufacturers in Jordan, Israel, China, and the US. Production capacity continues to grow, especially in Asian markets. Regulatory adherence and quality assurance remain critical factors influencing supplier choice.
Key Takeaways
- Amikacin sulfate is produced predominantly by generic manufacturers, with Hikma, Mylan, and Teva leading global supply.
- Emerging manufacturers in China expand capacity to meet rising global demand driven by bacterial resistance.
- Price varies by quality certifications and regional manufacturing standards.
- Supply chain stability depends on raw material sourcing from Asia and adherence to regulatory standards.
- Market growth remains steady, reinforced by increasing antibiotic resistance.
FAQs
1. Are there any patent restrictions on amikacin sulfate?
Most patents expired in multiple regions, allowing generic manufacturers to produce it freely. Licensing agreements may still exist in specific markets.
2. Can I source amikacin sulfate from manufacturers in China?
Yes. Several Chinese companies, such as Zhejiang Huahai Pharmaceutical and Zhejiang Tianyang Pharmaceutical, produce amikacin sulfate conforming to international quality standards.
3. What quality certifications should suppliers have?
Manufacturers should have WHO-GMP, US FDA approval, or European CE marking to ensure compliance with international standards.
4. Is there a significant difference in price between suppliers?
Price variability exists, influenced by quality standards, certification, and supply volume. Average prices per vial range from USD 3.50 to USD 6.20.
5. How do supply chain disruptions affect availability?
Raw material shortages, manufacturing delays, or regulatory issues can disrupt supplies. Sourcing from multiple suppliers in different regions mitigates risk.
References
- Pfizer Inc. (2022). Pfizer Annual Report 2022.
- Zhejiang Huahai Pharmaceutical. (2023). Annual Production Capacity Report.
- Teva Pharmaceutical Industries. (2022). Regulatory Compliance and GMP Certification Data.
- MarketWatch. (2022). Antibiotic Market Analysis.
- WHO. (2022). Prequalification of Medicines Program.
[1] All data derived from industry reports, regulatory filings, and company disclosures as of 2023.
